Both peptides lack tumor-promoting activity in published studies, and neither affects cortisol, prolactin, or other hormonal axes
The theoretical extension of this rationale to retatrutide is scientifically plausible but remains exploratory
This permanent commitment factor influences many users treatment decisions and overall satisfaction
A study (PMID: 38879894) examined GHK-Cu complexes targeting lung inflammation and fibrosis, finding that the compound modulated inflammatory and fibrotic markers in tissue models
It is the most common route for musculoskeletal applications because it allows proximal injection near the injury site, which appears to improve local tissue concentration based on animal study findings
The injectable GHK-Cu peptide has some promising science, but its currently not approved for systemic use by the FDA